{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:52:41Z","timestamp":1790941961479,"version":"4.1.0"},"reference-count":172,"publisher":"Japanese Pharmacological Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2003]]},"DOI":"10.1254\/jphs.93.381","type":"journal-article","created":{"date-parts":[[2004,1,22]],"date-time":"2004-01-22T06:03:03Z","timestamp":1074751383000},"page":"381-396","source":"Crossref","is-referenced-by-count":85,"title":["Platelets and Anti-platelet Therapy"],"prefix":"10.1254","volume":"93","author":[{"given":"Archibald","family":"McNicol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara J.","family":"Israels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"332","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Handin RI. Platelets and coronary artery disease. N Eng J Med. 1996;334:1126–1127.","DOI":"10.1056\/NEJM199604253341710"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8:1227–1234.","DOI":"10.1038\/nm1102-1227"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 McNicol A, Gerrard JM. Platelet morphology, aggregation and secretion. In: Advances in molecular and cell biology. Greenwich: JAI Press Inc.; 1997. p. 1–29.","DOI":"10.1016\/S1569-2558(08)60409-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Clutton P, Folts JD, Freedman JE. Pharmacological control of platelet function. Pharmacol Rev. 2001;44:255–264.","DOI":"10.1006\/phrs.2001.0861"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev. 2003;2:16–28.","DOI":"10.1038\/nrd985"},{"key":"6","unstructured":"6 White JG. Interaction of platelet membrane systems in blood platelets. Am J Pathol. 1972;95:295–312."},{"key":"7","unstructured":"7 Drummond AH, MacIntyre DE. Platelet inositol lipid metabolism and calcium flux. In: Platelets in biology and pathology III. Amsterdam: Elsevier\/North Holland; 1987. p. 373–431."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Rosado JA, Sage SO. Activation of store-mediated calcium entry by secretion-like coupling between the inositol 1,4,5-trisphosphate receptor type II and human transient receptor potential (hTrp1) channels in human platelets. Biochem J. 2001;356:191–198.","DOI":"10.1042\/bj3560191"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Lagarde M, Menashi S, Crawford N. Localisation of phospholipase A2 and diglyceride lipase activities in human platelet intracellular membranes. FEBS Lett. 1981;124:23–26.","DOI":"10.1016\/0014-5793(81)80045-2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Carey F, Menashi S, Crawford N. Localization of cyclo-oxygenase and thromboxane synthetase in human platelet intracellular membranes. Biochem J. 1982;204:847–851.","DOI":"10.1042\/bj2040847"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Harrison P, Cramer EM. Platelet alpha-granules. Blood Rev. 1993;7:52–62.","DOI":"10.1016\/0268-960X(93)90024-X"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Rendu F, Brohard-Bohn B. The platelet release reaction: granules’ constituents, secretion and functions. Platelets. 2001;12:261–273.","DOI":"10.1080\/09537100120068170"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 McNicol A, Israels SJ. Platelet dense granules:structure, function and implications for haemostasis. Thromb Res. 1999;95:1–18.","DOI":"10.1016\/S0049-3848(99)00015-8"},{"key":"14","unstructured":"14 van Oost BA. Acid hydrolase secretion. In: Platelet responses and metabolism II. Boca Raton: CRC Press Inc.; 1986. p. 163–191."},{"key":"15","unstructured":"15 McNicol A, Israels SJ, Gerrard JM. Platelets. Recent advances in blood coagulation 6, Edinburgh: Churchill Livingstone Ltd.; 1993. p. 17–49."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Furie B, Furie BC, Flaumenhaft R. A journey with platelet P-selectin: the molecular basis of granule secretion, signalling and cell adhesion. Thromb Haemost. 2001;86:214–221.","DOI":"10.1055\/s-0037-1616219"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Shattil SJ. Signaling through platelet integrin alpha IIb beta 3: inside-out, outside-in, and sideways. Thromb Haemost. 1999;82:318–325.","DOI":"10.1055\/s-0037-1615849"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Sims PJ, Wiedmer T. Unraveling the mysteries of phospholipid scrambling. Thromb Haemost. 2001;86:266–275.","DOI":"10.1055\/s-0037-1616224"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. Part I. N Engl J Med. 1992;326:242–250.","DOI":"10.1056\/NEJM199201233260406"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. Part II. N Engl J Med. 1992;326:310–318.","DOI":"10.1056\/NEJM199201303260506"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Ross R. Athersoclerosis — an inflammatory disease. N Engl J Med. 1999;340:115–126.","DOI":"10.1056\/NEJM199901143400207"},{"key":"22","unstructured":"22 Springer TA, Cybulsky MI. Traffic signals on endothelium for leukocytes in health inflammation and atherosclerosis. In: Fuster V, Ross R, Topol EJ, editors. Atherosclerosis and coronary artery disease Vol. 1. Philadelphia: Lippincott-Raven; 1996. p. 511–538."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Lin MC, Almus-Jacobs F, Chen HH, et al. Shear stress induction of the tissue factor gene. J Clin Invest. 1997;99:737–744.","DOI":"10.1172\/JCI119219"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Nakashima Y, Raines EW, Plump AS, Beslow JL, Ross R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the Apo-E deficient mouse. Arterioscler Thromb Vasc Biol. 1998;18:842–851.","DOI":"10.1161\/01.ATV.18.5.842"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Hynes RO, Wagner DD. Genetic manipulation of vascular adhesion molecules in mice. J Clin Invest. 1996;98:2193–2195.","DOI":"10.1172\/JCI119027"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26 Fitizgerald DJ. Vascular biology of thrombosis: the role of platelet-vessel wall adhesion. Neurology. 2001;57 Suppl 2:S1–S4.","DOI":"10.1159\/000047222"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Ruggeri ZM. Old concepts and new developments in the study of platelet aggregation. J Clin Invest. 2000;105:699–701.","DOI":"10.1172\/JCI9604"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Schneider DJ, Tracy PB, Sobel BE. Acute coronary syndromes: 1. The platelet’s role. Hosp Pract. 1998:33:171–185.","DOI":"10.1080\/21548331.1998.11443661"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Patrono C. Aspirin as an anti-platelet drug. N Engl J Med. 1994;330:1287–1294.","DOI":"10.1056\/NEJM199405053301808"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Smith W, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996;271:157–160.","DOI":"10.1074\/jbc.271.52.33157"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol. 1992;263:F181–F191.","DOI":"10.1152\/ajprenal.1992.263.2.F181"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Fitzgerald GA. Mechanisms of platelets activation:thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol. 1991;68:11B–15B.","DOI":"10.1016\/0002-9149(91)90379-Y"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci. 1975;72:3073–3076.","DOI":"10.1073\/pnas.72.8.3073"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. J Clin Invest. 1975;56:624–632.","DOI":"10.1172\/JCI108132"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthase by oral aspirin. J Clin Invest. 1978;61:314–319.","DOI":"10.1172\/JCI108941"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809–1817.","DOI":"10.1056\/NEJMoa003199"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 de Gaetano G, Donati MB, Cerletti C. Prevention of thrombosis and vascular inflammation:benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. Trends Pharmacol Sci. 2003;24:245–252.","DOI":"10.1016\/S0165-6147(03)00077-4"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofexcoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520–1528.","DOI":"10.1056\/NEJM200011233432103"},{"key":"39","doi-asserted-by":"publisher","unstructured":"39 Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and the risk of serious coronary heart disease. Lancet. 2002;360:1071–1073.","DOI":"10.1016\/S0140-6736(02)11131-7"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Marcus AA, Broekman MJ, Pinsky DJ. COX inhibitors and thromboregulation. N Engl J Med. 2002;347:1025–1026.","DOI":"10.1056\/NEJMcibr021805"},{"key":"41","first-page":"349","volume":"2","year":"1988","unstructured":"41 Second International Study of Infarct Survival Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected myocardial infarction: ISIS-2. Lancet. 1988;2:349–360.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Aspirin Trialists’ Collaboration. Collaborative overview of randomized trials of anti-platelet therapy-I: prevention of death, myocardial infarction, stroke by prolonged anti-platelet therapy in various categories of patients. Br Med J. 1994;308:81–106.","DOI":"10.1136\/bmj.308.6921.81"},{"key":"43","doi-asserted-by":"publisher","unstructured":"43 Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs. The relationships among dose, effectiveness, and side effects. Chest. 2001;119:39S–63S.","DOI":"10.1378\/chest.119.1_suppl.39S"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of anti-platelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. Br Med J. 2002;324:71–86.","DOI":"10.1136\/bmj.324.7329.71"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing physicians’ health study. N Engl J Med. 1989;321:129–135.","DOI":"10.1056\/NEJM198907203210301"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Mehta J, Mehta P, Burger C, et al. Platelet aggregation studies in coronary artery disease. Atherosclerosis. 1978;31:169–175.","DOI":"10.1016\/0021-9150(78)90162-4"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;8:230–235.","DOI":"10.1016\/S0002-9149(01)01631-9"},{"key":"48","doi-asserted-by":"publisher","unstructured":"48 Eikelboom JW, Hirsch J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular events. Circulation. 2002;105:1650–1655.","DOI":"10.1161\/01.CIR.0000013777.21160.07"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost. 2002;88:711–715.","DOI":"10.1055\/s-0037-1613290"},{"key":"50","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1161\/01.CIR.101.9.1013","volume":"101","year":"2000","unstructured":"50 Michelson AD, Furman MI, Goldschmidt-Clermont P, et al. Platelet GPIIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation. 2000;101:1013–1018.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med. 2001;138:152–163.","DOI":"10.1067\/mlc.2001.117406"},{"key":"52","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1161\/01.CIR.89.2.588","volume":"89","year":"1994","unstructured":"52 The RAPT Trial Investigators. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2\/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myoocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation. 1994;89:588–595.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Diener HC, Cunha L, Forbes C, et al. European stroke prevention study II: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1–13.","DOI":"10.1016\/S0022-510X(96)00308-5"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Nurden AT, Nurden P, George JN. Are patients with Glanzmann Thrombasthenia and the Bernard-Soulier Syndrome protected against atherosclerosis? In: Monroe et al., editors. Hemophilia care in the new millennium. Kluwer Academic\/Plenum Publishers; 2001. p. 13–29.","DOI":"10.1007\/978-1-4615-1277-6_2"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Casserly IP, Topol EJ. Glycoprotein IIb\/IIIa antagonists — from bench to practice. Cell Mol Life Sci. 2002;59:478–500.","DOI":"10.1007\/s00018-002-8440-8"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Coller BS. Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: with a review of platelet-leukocyte interactions. Thromb Haemost. 1999;82:326–336.","DOI":"10.1055\/s-0037-1615850"},{"key":"57","first-page":"1757","volume":"90","year":"1999","unstructured":"57 Steinbuhl SR, Kottke-Marchant K, Moliterno DJ, et al. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation. 1999;90:1757–1764.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"58","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1161\/01.CIR.103.21.2572","volume":"103","year":"2001","unstructured":"58 Steinhubl SR, Talley JD, Braden GA, et al. Pont-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention:results of the GOLD(AU-assessing ultegra) multicenter study. Circulation. 2001;103:2572–2578.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"59","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1161\/01.CIR.97.17.1680","volume":"97","year":"1998","unstructured":"59 Macelli MA, Lance ET, Damrarju L, et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhbition with gradual recovery from GPIIb\/IIIa receptor blockade. Circulation. 1998;97:1680–1688.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956–961.","DOI":"10.1056\/NEJM199404073301402"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 EPILOG Investigators. Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1623–1629.","DOI":"10.1056\/NEJM199706123362401"},{"key":"62","doi-asserted-by":"publisher","unstructured":"62 CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429–1435.","DOI":"10.1016\/S0140-6736(96)10452-9"},{"key":"63","doi-asserted-by":"publisher","unstructured":"63 EPISTENT Investigators. Randomised placebo-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb\/IIIa blockade. Lancet. 1998;352:87–92.","DOI":"10.1016\/S0140-6736(98)85010-1"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomised, placebo-controlled trials of percutaneous coronary revascularization. Am J Med. 2002;113:1–6.","DOI":"10.1016\/S0002-9343(02)01145-2"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65 Madan M, Berkowitz SD. Understanding thrombocytopenia and antigenicity with glycoprotein IIb – IIIa inhibitors. Am Heart J. 1999;138:317–326.","DOI":"10.1053\/hj.1999.v138.a100465"},{"key":"66","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1161\/01.CIR.95.4.809","volume":"95","year":"1997","unstructured":"66 Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after C7E3 (abciximab) therapy. Circulation. 1997;95:809–813.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Abrams S, Cines DB. Platelet glycoprotein IIb\/IIIa inhibitors and thrombocytopenia: possible link between platelet activation, autoimmunity and thrombosis. Thromb Haemost. 2002;88:888–889.","DOI":"10.1055\/s-0037-1613328"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68 Tcheng JE, Kereiakes DJ, Braden GA, et al. Readministration of abciximab: interim report of the ReoPro readministration registry. Am Heart J. 1999;138:S33–S38.","DOI":"10.1053\/hj.1999.v138.99236"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69 Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol. 1997;80:11B–20B.","DOI":"10.1016\/S0002-9149(97)00572-9"},{"key":"70","first-page":"199","volume":"349","year":"1997","unstructured":"70 IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. 1997;349:199–224.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 PURSUIT trial investigators. Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndrome. Platelet glycoprotein IIb\/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med. 1998;339:436–443.","DOI":"10.1056\/NEJM199808133390704"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72 Cook JJ, Bednar B, Lynch JL Jr, et al. Trofiban (Aggrastat®<\/sup>). Cardiovasc Drug Rev. 1999;17:199–224.","DOI":"10.1111\/j.1527-3466.1999.tb00015.x"},{"key":"73","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/01.CIR.96.5.1445","volume":"96","year":"1997","unstructured":"73 RESTORE Investigators. Effects of platelet glycoprotein IIb\/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcome and REstenosis. Circulation. 1997;96:1445–1453.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74 PRISM Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498–1505.","DOI":"10.1056\/NEJM199805213382103"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75 PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488–1497.","DOI":"10.1056\/NEJM199805213382102"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76 O’Neill WW, Serruys P, Knudtson M, et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of oral xamilofiban in controlling thrombotic events. N Eng J Med. 2000;342:316–1324.","DOI":"10.1056\/NEJM200005043421803"},{"key":"77","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.CIR.102.2.149","volume":"102","year":"2000","unstructured":"77 Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb\/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000;102:149–156.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"78","doi-asserted-by":"publisher","unstructured":"78 The SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Sibrafiban versus aspirin to yield maximum protection form ischemic heart events post-acute coronary syndromes. Lancet. 2000;355:337–345.","DOI":"10.1016\/S0140-6736(99)11179-6"},{"key":"79","doi-asserted-by":"publisher","unstructured":"79 Chew DP, Bhatt DL, Sapp S, et al. Increased mortality with oral platelet glycoprotein IIb\/IIIa antagonists:a meta-analysis of phase III multicenter randomized trials. Circulation. 2001;103:201–206.","DOI":"10.1161\/01.CIR.103.2.201"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80 Chew DP, Bhatt DL, Topol EJ. Oral glycoprotein IIb\/IIIa inhibitors;why don’t they work? Am J Cardiovasc Drugs. 2001;1:421–428.","DOI":"10.2165\/00129784-200101060-00002"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81 Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet GP IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888–1894.","DOI":"10.1056\/NEJM200106213442502"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82 Gawaz M, Ruf A, Pogatsa-Murray G, et al. Incomplete inhibition of platelet aggregation and glycoprotein IIb – IIIa receptor blockade by abciximab: Importance of internal pool of glycoprotein IIb – IIIa receptors. Thromb Haemost. 2000;83:915–922.","DOI":"10.1055\/s-0037-1613921"},{"key":"83","doi-asserted-by":"publisher","unstructured":"83 GUSTO IV-ACS Investigators. Effect of GPIIb\/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndrome without early coronary revascularisation:the GUSTO IV-ACS trial. Lancet. 2001;357:1915–1924.","DOI":"10.1016\/S0140-6736(00)05060-1"},{"key":"84","doi-asserted-by":"publisher","unstructured":"84 Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb\/IIIa inhibitors. Recognition of a two-edged sword? Circulation. 2002;106:379–385.","DOI":"10.1161\/01.CIR.0000019581.22812.B2"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85 Cox D, Smith R, Quinn M, et al. Evidence of platelet activation during treatment with a GPIIb\/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol. 2000;36:1514–1519.","DOI":"10.1016\/S0735-1097(00)00919-0"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86 Neumann FJ, Zohlnhofer D, Fakhoury L, et al. Effect of glycoprotein IIb\/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol. 1999;34:1420–1426.","DOI":"10.1016\/S0735-1097(99)00350-2"},{"key":"87","first-page":"311","volume":"104","year":"2001","unstructured":"87 Nannizzi-Alaimo N, Alves VL, Prasad S, et al. GPIIb\/IIIa antagonists demonstrate a dose-dependent inhibition and potentiation of soluble CD40L (CD154) release during platelet stimulation. Circulation. 2001;104:311–318.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"88","doi-asserted-by":"crossref","unstructured":"89 Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104–1111.","DOI":"10.1056\/NEJMoa022600"},{"key":"89","unstructured":"90 Braunwald E, Antman EM, Beasley JW, et al. ACC\/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendation. A report of the American college of Cardiology\/American Heart Association task form on practice guidelines. Available at: URL: http:\/\/www.americanheart.org\/downladable\/heart\/1016214837537 UANSTEMI2002Web.pdf"},{"key":"90","doi-asserted-by":"crossref","unstructured":"91 Daniel JL, Dangelmaier C, Jin J, et al. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem. 1998;273:2024–2029.","DOI":"10.1074\/jbc.273.4.2024"},{"key":"91","doi-asserted-by":"crossref","unstructured":"92 Barnard EA, Simon J. An elusive receptor is finally caught: P2Y(12'), an important drug target in platelets. Trends Pharmacol Sci. 2001;22:388–391.","DOI":"10.1016\/S0165-6147(00)01759-4"},{"key":"92","doi-asserted-by":"crossref","unstructured":"93 Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost. 2001;86:222–232.","DOI":"10.1055\/s-0037-1616220"},{"key":"93","doi-asserted-by":"crossref","unstructured":"94 Kunapuli SP, Dorsam RT, Kim S, et al. Platelet purinergic receptors. Curr Opin Pharmacol. 2003;3:175–180.","DOI":"10.1016\/S1471-4892(03)00007-9"},{"key":"94","doi-asserted-by":"publisher","unstructured":"95 Levy-Toledano S. Platelet signal transduction pathways:could we organize them into a ‘hierarchy’? Haemostasis. 1999;29:4–15.","DOI":"10.1159\/000022456"},{"key":"95","doi-asserted-by":"crossref","unstructured":"96 Sage SO. The Wellcome Prize Lecture. Calcium entry mechanisms in human platelets. Exp Physiol. 1997;82:807–823.","DOI":"10.1113\/expphysiol.1997.sp004066"},{"key":"96","doi-asserted-by":"crossref","unstructured":"97 Kauffenstein G, Bergmeier W, Eckly A, et al. The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin — a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett. 2001;505:281–290.","DOI":"10.1016\/S0014-5793(01)02824-1"},{"key":"97","doi-asserted-by":"publisher","unstructured":"98 Jin J, Quinton TM, Zhang J et al. Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors. Blood. 2002;99:193–198.","DOI":"10.1182\/blood.V99.1.193"},{"key":"98","unstructured":"99 Cattaneo M, Gachet C. The platelet ADP receptors. Haematol. 2001;86:346–348."},{"key":"99","unstructured":"100 Gachet C. Platelet activation by ADP: the role of ADP antagonists. Ann Med. 2000; 32 Suppl 1:15–20."},{"key":"100","doi-asserted-by":"publisher","unstructured":"101 Kam PCA, Nethery CM. The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia. 2003;58:28–35.","DOI":"10.1046\/j.1365-2044.2003.02960.x"},{"key":"101","doi-asserted-by":"publisher","unstructured":"102 Jarvis B, Simpson K. Clopidogrel:a review of its use in the prevention of atherothrombosis. Drugs. 2000;60:347–377.","DOI":"10.2165\/00003495-200060020-00012"},{"key":"102","doi-asserted-by":"crossref","unstructured":"103 Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost. 1994;72:313–317.","DOI":"10.1055\/s-0038-1648859"},{"key":"103","doi-asserted-by":"crossref","unstructured":"104 Steinhubl SR, Tan WA, Foody JM, et al. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb\/IIIa Inhibitor for Stenting. J Am Med Assoc. 1999;281:806–810.","DOI":"10.1001\/jama.281.9.806"},{"key":"104","doi-asserted-by":"crossref","unstructured":"105 Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84:891–896.","DOI":"10.1055\/s-0037-1614133"},{"key":"105","doi-asserted-by":"crossref","unstructured":"106 Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002;30:1288–1295.","DOI":"10.1124\/dmd.30.11.1288"},{"key":"106","doi-asserted-by":"crossref","unstructured":"107 CAPRIE Investigators. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol. 2002;90:760–762.","DOI":"10.1016\/S0002-9149(02)02606-1"},{"key":"107","doi-asserted-by":"crossref","unstructured":"108 CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.","DOI":"10.1056\/NEJMoa010746"},{"key":"108","doi-asserted-by":"crossref","unstructured":"109 Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665–1671.","DOI":"10.1056\/NEJM199812033392303"},{"key":"109","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1161\/01.CIR.98.20.2126","volume":"98","year":"1998","unstructured":"110 Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation. 1998;98:2126–2132.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"110","doi-asserted-by":"crossref","unstructured":"111 Schomig A, Neumann FJ, Walter H, et al. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol. 1997;29:28–34.","DOI":"10.1016\/S0735-1097(96)00450-0"},{"key":"111","doi-asserted-by":"crossref","unstructured":"112 CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000;102:624–629.","DOI":"10.1161\/01.CIR.102.6.624"},{"key":"112","doi-asserted-by":"crossref","unstructured":"113 Storey RF, Newby LJ, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets. 2001;12:443–447.","DOI":"10.1080\/09537100120085450"},{"key":"113","doi-asserted-by":"crossref","unstructured":"114 Storey RF, Judge HM, Wilcox RG et al. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost. 2002;88:488–494.","DOI":"10.1055\/s-0037-1613242"},{"key":"114","doi-asserted-by":"crossref","unstructured":"115 Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets. 2002;13:407–413.","DOI":"10.1080\/0953710021000024402"},{"key":"115","doi-asserted-by":"crossref","unstructured":"116 Wang K, Zhou X, Zhou Z et al. Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. Arterioscler Thromb Vasc Biol. 2003;23:357–562.","DOI":"10.1161\/01.ATV.0000052669.50791.0B"},{"key":"116","doi-asserted-by":"crossref","unstructured":"117 McNicol A, Gerrard JM. Post-receptor events associated with thrombin-induced platelet activation. Blood Coag Fibrinolysis. 1993;4:975–991.","DOI":"10.1097\/00001721-199312000-00014"},{"key":"117","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/29325","volume":"394","year":"1998","unstructured":"118 Kahn ML, Zheng YW, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature. 1998;394:690–694.","journal-title":"?Nature","ISSN":"https:\/\/id.crossref.org\/issn\/0028-0836","issn-type":"print"},{"key":"118","doi-asserted-by":"crossref","unstructured":"119 Kahn ML, Nakanishi-Matsui M, Shapiro MJ, et al. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999;103:879–887.","DOI":"10.1172\/JCI6042"},{"key":"119","doi-asserted-by":"crossref","unstructured":"120 Coughlin SR. Protease-activated receptors and platelet function. Thromb Haemost. 1999;82:353–356.","DOI":"10.1055\/s-0037-1615853"},{"key":"120","doi-asserted-by":"crossref","unstructured":"121 Coughlin SR. Protease-activated receptors in vascular biology. Thromb Haemost. 2001;86:298–307.","DOI":"10.1055\/s-0037-1616227"},{"key":"121","doi-asserted-by":"crossref","unstructured":"122 De Candia E, Hall SW, Rutella S, et al. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem. 2001;276:4692–4698.","DOI":"10.1074\/jbc.M008160200"},{"key":"122","doi-asserted-by":"crossref","unstructured":"123 Andrade-Gordon P, Maryanoff BE, Derian CK, et al. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci USA. 1999;96:12257–12262.","DOI":"10.1073\/pnas.96.22.12257"},{"key":"123","doi-asserted-by":"crossref","unstructured":"124 Wu CC, Huang SW, Hwang TL, et al. YD-3, a novel inhibitor of protease-induced platelet activation. Br J Pharmacol. 2000;130:1289–1296.","DOI":"10.1038\/sj.bjp.0703437"},{"key":"124","doi-asserted-by":"crossref","unstructured":"125 Covic L, Gresser AL, Talavera J, et al. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci USA. 2002;99:643–648.","DOI":"10.1073\/pnas.022460899"},{"key":"125","doi-asserted-by":"crossref","unstructured":"126 Stephens G, O’Luanaigh N, Reilly D, et al. A sequence within the cytoplasmic tail of GpIIb independently activates platelet aggregation and thromboxane synthesis. J Biol Chem. 1998;273:20317–20322.","DOI":"10.1074\/jbc.273.32.20317"},{"key":"126","doi-asserted-by":"publisher","unstructured":"127 Nakata M, Yada T, Soejima N, et al. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes. 1999;48:426–429.","DOI":"10.2337\/diabetes.48.2.426"},{"key":"127","doi-asserted-by":"crossref","unstructured":"128 Margetic S, Gazzola C, Pegg GG, et al. Leptin:a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord. 2002;26:1407–1433.","DOI":"10.1038\/sj.ijo.0802142"},{"key":"128","doi-asserted-by":"crossref","unstructured":"129 Konstantinides S, Schafer K, Koschnick S, et al. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest. 2001;108:1533–1540.","DOI":"10.1172\/JCI13143"},{"key":"129","doi-asserted-by":"crossref","unstructured":"130 Corsonello A, Perticone F, Malara A, et al. Leptin-dependent platelet aggregation in healthy, overweight and obese subjects. Int J Obes Relat Metab Disord. 2003;27:566–567.","DOI":"10.1038\/sj.ijo.0802273"},{"key":"130","doi-asserted-by":"crossref","unstructured":"131 Ozata M, Avcu F, Durmus O, et al. Leptin does not play a major role in platelet aggregation in obesity and leptin deficiency. Obes Res. 2001;9:627–630.","DOI":"10.1038\/oby.2001.82"},{"key":"131","doi-asserted-by":"crossref","unstructured":"132 Konstantinides S, Schafer K, Loskutoff DJ. The prothrombotic effects of leptin:possible implications for the risk of cardiovascular disease in obesity. Ann NY Acad Sci. 2001;947:134–141.","DOI":"10.1111\/j.1749-6632.2001.tb03936.x"},{"key":"132","doi-asserted-by":"crossref","unstructured":"133 Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:85–102.","DOI":"10.1016\/S0278-5846(02)00338-X"},{"key":"133","doi-asserted-by":"crossref","unstructured":"134 Green B. Focus on paroxetine. Curr Med Res Opin. 2003;19:13–21.","DOI":"10.1185\/030079902125001353"},{"key":"134","doi-asserted-by":"crossref","unstructured":"135 Ottervanger JP, Stricker BH, Huls J, et al. Bleeding attributed to the intake of paroxetine. Am J Psychiatry. 1994;151:781–782.","DOI":"10.1176\/ajp.151.5.781"},{"key":"135","doi-asserted-by":"crossref","unstructured":"136 de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. Br Med J. 1999;319:1106–1109.","DOI":"10.1136\/bmj.319.7217.1106"},{"key":"136","doi-asserted-by":"crossref","unstructured":"137 Layton D, Clark DW, Pearce GL, et al. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England. Eur J Clin Pharmacol. 2001;57:167–176.","DOI":"10.1007\/s002280100263"},{"key":"137","doi-asserted-by":"crossref","unstructured":"138 Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003;163:59–64.","DOI":"10.1001\/archinte.163.1.59"},{"key":"138","doi-asserted-by":"crossref","unstructured":"139 Pletscher A. The 5-hydroxytryptamine system of blood platelets: physiology and pathophysiology. Int J Cardiol. 1987;14:177–188.","DOI":"10.1016\/0167-5273(87)90007-6"},{"key":"139","doi-asserted-by":"crossref","unstructured":"140 Affolter H, Erne P, Burgisser E, et al. A Ca2+ as messenger of 5HT2-receptor stimulation in human blood platelets. Naunyn Schmiedebergs Arch Pharmacol. 1984;325:337–342.","DOI":"10.1007\/BF00504378"},{"key":"140","doi-asserted-by":"crossref","unstructured":"141 Menys VC, Smith CC, Lewins P, et al. Platelet 5-hydroxytryptamine is decreased in a preliminary group of depressed patients receiving the 5-hydroxytryptamine re-uptake inhibiting drug fluoxetine. Clin Sci (Lond). 1996;91:87–92.","DOI":"10.1042\/cs0910087"},{"key":"141","doi-asserted-by":"crossref","unstructured":"142 Butler J, Leonard BE. The platelet serotonergic system in depression and following sertraline treatment. Int Clin Psychopharmacol. 1988;3:343–347.","DOI":"10.1097\/00004850-198810000-00005"},{"key":"142","doi-asserted-by":"crossref","unstructured":"143 Wgner A, Montero D, Martensson B, et al. Effects of fluoxetine treatment of platelet 3H-imipramine binding, 5-HT uptake and 5-HT content in major depressive disorder. J Affect Disord. 1990;20:101–113.","DOI":"10.1016\/0165-0327(90)90123-P"},{"key":"143","doi-asserted-by":"crossref","unstructured":"144 Alderman CP, Moritz CK, Ben-Tovim DI. Abnormal platelet aggregation associated with fluoxetine therapy. Ann Pharmacother. 1992;26:1517–1519.","DOI":"10.1177\/106002809202601205"},{"key":"144","doi-asserted-by":"crossref","unstructured":"145 Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol. 2000;20:137–140.","DOI":"10.1097\/00004714-200004000-00004"},{"key":"145","doi-asserted-by":"crossref","unstructured":"146 Serebruany VL, Gurbel PA, O’Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline:a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res. 2001;43:453–462.","DOI":"10.1006\/phrs.2001.0817"},{"key":"146","doi-asserted-by":"crossref","unstructured":"147 Alderman CP, Seshadri P, Ben-Tovim DI. Effects of serotonin reuptake inhibitors on hemostasis. Ann Pharmacother. 1996;30:1232–1234.","DOI":"10.1177\/106002809603001103"},{"key":"147","doi-asserted-by":"crossref","unstructured":"148 Ohsuka N, Mashiko H, Kaneko M, et al. Effects of Antidepressants and antipsychotics on the 5HT2 receptor-mediated signal transducing system in human platelets. Psychopharmacology (Berl). 1995;121:428–432.","DOI":"10.1007\/BF02246490"},{"key":"148","doi-asserted-by":"crossref","unstructured":"149 Helmeste DM, Tang SW, Reist C, et al. Serotonin uptake inhibitors modulate intracellular Ca2+ mobilization in platelets. Eur J Pharmacol. 1995;288:373–377.","DOI":"10.1016\/0922-4106(95)90051-9"},{"key":"149","doi-asserted-by":"crossref","unstructured":"150 Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104:1894–1898.","DOI":"10.1161\/hc4101.097519"},{"key":"150","doi-asserted-by":"publisher","unstructured":"151 Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003;108:32–36.","DOI":"10.1161\/01.CIR.0000079172.43229.CD"},{"key":"151","doi-asserted-by":"crossref","unstructured":"152 Meier CR, Schlienger RG, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br J Clin Pharmacol. 2001;52:179–184.","DOI":"10.1046\/j.0306-5251.2001.01426.x"},{"key":"152","doi-asserted-by":"publisher","unstructured":"153 Bak S, Tsiropoulos I, Kjaersgaard JO, et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke. 2002;33:1465–1473.","DOI":"10.1161\/01.STR.0000018589.56991.BA"},{"key":"153","doi-asserted-by":"crossref","unstructured":"154 Ishimoto Y, Nakano T. Release of a product of growth arrest-specific gene 6 from rat platelets. FEBS Lett. 2000;466:197–199.","DOI":"10.1016\/S0014-5793(99)01795-0"},{"key":"154","unstructured":"155 García De Frutos P. Gas6. J Thromb Haemost. 2003;1 Suppl 1: SY53."},{"key":"155","unstructured":"156 Angelillo-Scherrer A, Charvier S, Plaisance S, et al. Deficiency in one Gas6 receptor (Axl, Sky or Mer) protects mice against thrombosis because of a platelet dysfunction. J Thromb Haemost. 2003;1 Suppl 1:OC245."},{"key":"156","doi-asserted-by":"crossref","unstructured":"157 Angelillo-Scherrer A, de Frutos P, Aparicio C, et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med. 2001;7:215–221.","DOI":"10.1038\/84667"},{"key":"157","doi-asserted-by":"crossref","unstructured":"158 Laman JD, De Boer M, Hart BA. CD40 in clinical inflammation: from multiple sclerosis to atherosclerosis. Dev Immunol. 1998;6:215–222.","DOI":"10.1155\/1998\/69628"},{"key":"158","doi-asserted-by":"crossref","unstructured":"159 Tan J, Town T, Mullan M. CD40-CD40L interaction in Alzheimer’s disease. Curr Opin Pharmacol. 2002;2:445–451.","DOI":"10.1016\/S1471-4892(02)00180-7"},{"key":"159","doi-asserted-by":"crossref","unstructured":"160 Libby P. Vascular biology of atherosclerosis:overview and state of the art. Am J Cardiol. 2003;91:3A–6A.","DOI":"10.1016\/S0002-9149(02)03143-0"},{"key":"160","doi-asserted-by":"crossref","unstructured":"161 Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998;16:111–135.","DOI":"10.1146\/annurev.immunol.16.1.111"},{"key":"161","doi-asserted-by":"crossref","unstructured":"162 Libby P, Mach F, Schonbeck U, et al. Regulation of the thrombotic potential of atheroma. Thromb Haemost. 1999;82:736–741.","DOI":"10.1055\/s-0037-1615905"},{"key":"162","doi-asserted-by":"crossref","unstructured":"163 Yellin MJ, Brett J, Baum D, et al. Functional interactions of T cells with endothelial cells:the role of CD40L-CD40-mediated signals. J Exp Med. 1995;182:1857–1864.","DOI":"10.1084\/jem.182.6.1857"},{"key":"163","doi-asserted-by":"publisher","unstructured":"164 Henn V, Steinbach S, Buchner K, et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 2001;98:1047–1054.","DOI":"10.1182\/blood.V98.4.1047"},{"key":"164","doi-asserted-by":"crossref","unstructured":"165 Inwald DP, McDowall A, Peters MJ, et al. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res. 2003;92:1041–1048.","DOI":"10.1161\/01.RES.0000070111.98158.6C"},{"key":"165","doi-asserted-by":"publisher","unstructured":"166 Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591–594.","DOI":"10.1038\/35393"},{"key":"166","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/01.CIR.100.6.614","volume":"100","year":"1999","unstructured":"167 Aukrust P, Muller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999;100:614–620.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"167","doi-asserted-by":"publisher","unstructured":"168 Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb\/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation. 2003;107:1123–1128.","DOI":"10.1161\/01.CIR.0000053559.46158.AD"},{"key":"168","doi-asserted-by":"publisher","unstructured":"169 Nannizzi-Alaimo L, Rubenstein MH, Alves VL, et al. Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation. 2002;105:2849–2854.","DOI":"10.1161\/01.CIR.0000019068.32280.B3"},{"key":"169","doi-asserted-by":"crossref","unstructured":"170 Peng DQ, Zhao SP, Li YF, et al. Elevated soluble CD40 ligand is related to the endothelial adhesion molecules in patients with acute coronary syndrome. Clin Chim Acta. 2002;319:19–26.","DOI":"10.1016\/S0009-8981(02)00014-1"},{"key":"170","doi-asserted-by":"crossref","unstructured":"171 Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104–1111.","DOI":"10.1056\/NEJMoa022600"},{"key":"171","doi-asserted-by":"crossref","unstructured":"172 Wang CL, Wu YT, Liu CA, et al. Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease. Pediatrics. 2003;111:E140–E147.","DOI":"10.1542\/peds.111.2.e140"},{"key":"172","doi-asserted-by":"crossref","unstructured":"173 Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin — dependent mechanism. Nat Med. 2002;8:247–252.","DOI":"10.1038\/nm0302-247"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T15:12:44Z","timestamp":1621437164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jphs\/93\/4\/93_4_381\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003]]},"references-count":172,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.93.381","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"value":"1347-8613","type":"print"},{"value":"1347-8648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003]]}}}